Amgen Inc. (AMGN) Shares Bought by Fisher Asset Management LLC
Fisher Asset Management LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 102,794 shares of the medical research company’s stock after buying an additional 1,221 shares during the period. Fisher Asset Management LLC’s holdings in Amgen were worth $17,147,000 as of its most recent filing with the SEC.
Other large investors also recently bought and sold shares of the company. Naples Global Advisors LLC boosted its position in shares of Amgen by 1.9% in the third quarter. Naples Global Advisors LLC now owns 16,228 shares of the medical research company’s stock worth $2,707,000 after buying an additional 308 shares during the period. Kelman Lazarov Inc. boosted its position in shares of Amgen by 7.3% in the third quarter. Kelman Lazarov Inc. now owns 1,756 shares of the medical research company’s stock worth $294,000 after buying an additional 120 shares during the period. Gradient Investments LLC boosted its position in shares of Amgen by 1.8% in the third quarter. Gradient Investments LLC now owns 30,739 shares of the medical research company’s stock worth $5,128,000 after buying an additional 537 shares during the period. Salem Capital Management Inc. acquired a new position in shares of Amgen during the third quarter worth $200,000. Finally, Gofen & Glossberg LLC IL boosted its position in shares of Amgen by 1.8% in the third quarter. Gofen & Glossberg LLC IL now owns 21,494 shares of the medical research company’s stock worth $3,585,000 after buying an additional 377 shares during the period. Institutional investors own 77.98% of the company’s stock.
Amgen Inc. (NASDAQ:AMGN) traded down 0.61% on Wednesday, reaching $145.11. 1,362,302 shares of the company’s stock traded hands. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $176.85. The firm’s 50-day moving average is $151.01 and its 200 day moving average is $160.49. The stock has a market capitalization of $107.95 billion, a PE ratio of 14.53 and a beta of 1.15.
Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, October 27th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.23. Amgen had a net margin of 33.63% and a return on equity of 29.27%. The business had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.73 billion. During the same period last year, the business posted $2.72 EPS. Amgen’s revenue was up 1.5% compared to the same quarter last year. Analysts forecast that Amgen Inc. will post $11.56 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 8th. Investors of record on Wednesday, November 16th will be paid a $1.00 dividend. The ex-dividend date is Monday, November 14th. This represents a $4.00 dividend on an annualized basis and a yield of 2.74%. Amgen’s payout ratio is presently 39.92%.
TRADEMARK VIOLATION WARNING: “Amgen Inc. (AMGN) Shares Bought by Fisher Asset Management LLC” was published by Financial Market News and is the propert of of Financial Market News. If you are accessing this news story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The original version of this news story can be accessed at http://www.financial-market-news.com/amgen-inc-amgn-shares-bought-by-fisher-asset-management-llc/1210713/.
AMGN has been the subject of a number of recent research reports. Leerink Swann reissued a “hold” rating on shares of Amgen in a research note on Saturday, September 17th. Goldman Sachs Group Inc. reaffirmed a “buy” rating and issued a $206.00 target price (up from $204.00) on shares of Amgen in a research note on Tuesday, September 27th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $190.00 target price on shares of Amgen in a research note on Thursday, September 22nd. Robert W. Baird reaffirmed an “outperform” rating and issued a $157.00 target price on shares of Amgen in a research note on Friday, August 26th. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Amgen in a research note on Wednesday, September 28th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the stock. Amgen currently has an average rating of “Buy” and an average price target of $182.04.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.